Thanks for your answer! I’m basically concerned in the M2M that the bloodwork will be great but the clinical won’t match completely because it’s subjective. Will those secondary endpoints count for much? With S2C the concern is hopefully we have no deaths in trial arms because those people are so sick that Leronlimab may not get in their systems in time to work. I believe the drug works amazingly but since the patient groups are so small there’s not a lot of room for error. How good do we have to be to get at least one approval? That’s what everyone should want to know right now.